NEUROCRINE BIOSCIENCES INC Lessor, Operating Lease, Payment to be Received, Year Three
NEUROCRINE BIOSCIENCES INC (NBIX) had Lessor, Operating Lease, Payment to be Received, Year Three of $3.60 million as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Notes › Leases › Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity
us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears · last filed 2026-07-31
- 2026-06-30: Lessor, Operating Lease, Payment to be Received, Year Three $3.60M.
- 2026-03-31: Lessor, Operating Lease, Payment to be Received, Year Three $3.60M.
- 2025-12-31: Lessor, Operating Lease, Payment to be Received, Year Three $4.00M.
- 2025-09-30: Lessor, Operating Lease, Payment to be Received, Year Three $3.50M.
| Period end | Lessor, Operating Lease, Payment to be Received, Year Three |
|---|---|
| 2026-06-30 | $3.60M 10-Q · filed 2026-07-31 |
| 2026-03-31 | $3.60M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $4.00M 10-K · filed 2026-02-11 |
| 2025-09-30 | $3.50M 10-Q · filed 2025-10-28 |
| 2025-06-30 | $3.50M 10-Q · filed 2025-07-30 |
| 2025-03-31 | $3.50M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $3.50M 10-K · filed 2025-02-10 |
| 2024-09-30 | $3.50M 10-Q · filed 2024-10-30 |
| 2024-06-30 | $2.70M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $1.70M 10-Q · filed 2024-05-01 |
| 2023-12-31 | $1.70M 10-K · filed 2024-02-09 |
| 2023-09-30 | $1.70M 10-Q · filed 2023-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |